Literature DB >> 2963304

[Treatment with a cefotaxime-fosfomycin combination of staphylococcal or enterobacterial meningitis in adults].

H Portier1, M Armengaud, B Becq-Giraudon, J Bousser, J M Desbordes, J M Duez, A Kazmierczak, A M Korinek, M J Laisne, B Pangon.   

Abstract

Thirty-two patients were included in this trial: 22 with staphylococcal meningitis (including 5 methicillin-resistant) and 10 with enterobacterial meningitis. Mean duration of treatment was 14.5 and 15.9 days respectively. The combination was synergistic in vitro against 10 of the 12 strains of Staphylococcus and 5 of the 6 strains of Enterobacteriaceae studied. Bacteriological sterilization occurred in all cases which could be evaluated, and clinical recovery was obtained in 95.2% of patients with staphylococcal meningitis (4 unrelated deaths) and 100% of patients with enterobacterial meningitis (2 deaths). Bactericidal power of the cerebro-spinal fluid, often less than 1/8, was not correlated with effectiveness against Staphylococci. Mean CSF concentrations of cefotaxime, desacetylcefotaxime and fosfomycin on the 2nd and 15th days of treatment were 4, 3.5 and 39.8 mg/l and 2.2, 2.1 and 28.0 mg/l, respectively. Clinical and biological acceptability was satisfactory. There were three cases of superinfection or colonization, by Pseudomonas and Enterobacter.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963304

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

Review 1.  Non-canonical mechanisms of antibiotic resistance.

Authors:  J L Martínez; J Blázquez; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.

Authors:  A del Río; C García-de-la-Mària; J M Entenza; O Gasch; Y Armero; D Soy; C A Mestres; J M Pericás; C Falces; S Ninot; M Almela; C Cervera; J M Gatell; A Moreno; P Moreillon; F Marco; J M Miró
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.